ArticleCureus2026
Pemigatinib-Associated Psoriasis in a Patient With Cholangiocarcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic autoimmune skin disease that may be triggered or exacerbated by medications, including targeted oncologic therapies. Pemigatinib is a fibroblast growth factor receptor inhibitor used for the treatment of cholangiocarcinoma. We present the case of a 61-year-old woman with unresectable cholangiocarcinoma and lung metastases who developed psoriatic plaques after four cycles of pemigatinib. She had a remote history of limited psoriasis but no other new triggers. Her presentation included occipital scalp and leg plaques. Topical therapies were prescribed; however, follow-up revealed persistent disease and uncertain treatment adherence. The patient ultimately deprioritized dermatologic symptoms in the context of systemic illness. To our knowledge, based on searches in PubMed and other databases, this represents the first reported case of pemigatinib-induced psoriasis. Recognition and management of dermatologic adverse effects are critical to minimizing morbidity in the setting of life-prolonging oncologic treatments. Given the limitations of a single-case inference, further surveillance and study are needed to determine whether patients with pre-existing psoriasis may be at increased risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.